Abstract: A microbial ethyl esther sophorolipid derivative with no acetylated groups produced by Candida species, for treating and preventing sepsis/septic shock. The method of producing sophorolipids is through microbial resting cells of Candida bombicola. The sophorolipids obtained from resting state cultures are isolated as a complex mixture of compounds and then decanted as a dense oil from the culture broth, subsequently washed to remove free fatty acids. Secondary chemical transformation via base catalyzed hydrolysis is used to reduce the 8 possible structural sophorolipid species to a single moiety, the 17-L-[(2?-O-b-D-glucopyranosyl-b-D-glucopyranosyl)-oxy]-cis-9-octadecenoate de-acetylated free acid. The compound acts primarily through decreasing inflammatory cytokines and eliciting other synergistic anti-inflammatory mechanisms by blocking TLR4-CD14 upstream of the inflammatory signaling cascade.

Abstract: Human polyclonal immunoglobulin M may be administered to patients suffering from a variety of immune-mediated diseases, including asthma, Common Variable Immunodeficiency (CVID), rheumatoid arthritis (RA), Systemic Lupus Erythmatosus (SLE), serum sickness and vasculitis, to treat the disease condition of those patients. Administration of immunoglobulin M results in a direct inhibitory effect on complement activity and a significant clinical improvement in the level of disease activity in patients with immune-mediated diseases.